| name | endo-statin-therapy-t1d-diabetic-retinopathy |
| description | Suggests statin therapy, irrespective of the cardiovascular risk score, to reduce cardiovascular risk in adults with type 1 diabetes and diabetic retinopathy. Trigger phrases include "Patient with T1D and diabetic retinopathy", "Considering statin for T1D with retinopathy", "Assessing cardiovascular risk in T1D with eye complications". |
Statin therapy for type 1 diabetes with diabetic retinopathy
STEP 1 — Gather Information
Confirm adult (≥18 years) with type 1 diabetes mellitus and documented diabetic retinopathy (e.g., ophthalmoscopy, fundus photography, or referral note). Obtain a lipid panel (LDL-C, HDL-C, triglycerides) and assess for contraindications (pregnancy, active liver disease, statin intolerance).
STEP 2 — Rule In / Rule Out
Rule in if the patient has type 1 diabetes and diabetic retinopathy. Rule out if pregnant, planning pregnancy, breastfeeding, or has absolute contraindications to statins (active liver disease, hypersensitivity).
STEP 3 — Classify or Stratify
If LDL‑C >70 mg/dL (1.8 mmol/L), classify as high‑intensity statin candidate; if LDL‑C ≤70 mg/dL, still classify as statin candidate but engage in shared decision‑making regarding intensity.
STEP 4 — Decide
Initiate a moderate‑ or high‑intensity statin (e.g., atorvastatin 10–20 mg daily, rosuvastatin 5–10 mg daily) unless contraindicated. Re‑check lipids and liver enzymes in 4–12 weeks, then periodically.
Clinical Guardrails / Mimics / Pitfalls
Do not prescribe statins in pregnancy or when pregnancy is planned. Avoid relying solely on cardiovascular risk scores; the recommendation applies regardless of score. Watch for drug interactions (e.g., with macrolides, azole antifungals) that increase statin‑related myopathy risk. Do not discontinue statin solely because LDL‑C falls below 70 mg/dL.
Concrete Clinical Example
A 45‑year‑old man with type 1 diabetes for 15 years has mild non‑proliferative diabetic retinopathy on screening and LDL‑C 68 mg/dL. Despite LDL‑C below the typical threshold, statin therapy is suggested irrespective of risk score; atorvastatin 10 mg daily is initiated.
Source: Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674
